Allergic sensitisations during the life course. Results of the KiGGS cohort

Background
Allergic sensitisations of the immune system involve the formation of specific immunoglobulin E (IgE) antibodies after (initial) contact with certain otherwise harmless substances (allergens). Repeated contact with allergens, however, sensitises the immune system. On subsequent contact, the immune system recognises these allergens and this triggers a reaction by its defence mechanisms. Allergic reactions can affect different organs, have different degrees of severity and show various symptoms. Although allergic sensitisations are measurable by analysing the levels of IgE antibodies in the blood, detecting these antibodies does not provide a measurement of disease, rather they are merely associated with an increased risk of allergic diseases [1].

There are four different types of allergic reaction. Type I hypersensitivity, also referred to as the immediate type, is the most common form and it is mediated by IgE antibodies. Some of the best known manifestations of Type I allergies include hay fever and (allergic) asthma. These conditions are among the most common chronic diseases in childhood and adolescence, they place significant burdens on health and have strong socioeconomic consequences [2, 3]. An important aspect of epidemiological allergy research is the extent to which sensitisations persist and how they may develop or even decline during the life course.

In particular, this applies to sensitisations to important inhalant allergens that play a significant role in the development of hay fever and asthma. Only limited data are available that can be used to calculate transition probabilities. However, as part of the KiGGS cohort – the largest cohort for children and adolescents in Germany – measurements were taken of important specific IgE antibodies that are associated with the most commonly occurring allergic diseases. These measurements were made during the KiGGS baseline study (2003-2006) and KiGGS Wave 2 (2014-2017). This data can help answer the important question about the extent to which allergic sensitisations persist, arise or even decline over a period of more than ten years. This article, therefore, uses the longitudinal data from the KiGGS cohort to investigate the transition probabilities of allergic sensitisations during the transition from childhood to young adulthood.

Indicator and methodology
The analyses are based on measurements made of specific IgE antibodies that react against the allergen mixture SX1, a mixture of eight common inhalant allergens (timothy, rye-grass, birch, mugwort, cat and dog dander, house dust mite and the fungus Cladosporium herbarum – Phadia, now Thermo Scientific, Freiburg). Measurements were made
from 2,041 girls and 2,143 boys who participated in the cohort study and who were examined both during the baseline study (2003-2006) and during KiGGS Wave 2 (2014-2017). The participants were aged 3 years or older at the time of the first measurement. Transition probabilities were calculated as the percentage probability of a transition from non-sensitisation to sensitisation to the allergen mixture SX1 or vice versa during the period beginning with the KiGGS baseline study and ending with KiGGS Wave 2. The value of ≥0.35 kU/l was used to set the limit of positive sensitisations. A possible bias due to selective re-participation was partially offset by multivariate weighting [4, 5].

Figure 1: Sensitisation to an allergen mixture of eight common inhalant allergens (SX1 test) over a 10-year period of the life course (n=2,041 girls, n=2,143 boys)

Sensitisation to SX1 test over a 10-year period of the life course

Girls ≥3 years KiGGS baseline study
Girls ≥13 years KiGGS Wave 2

Boys ≥3 years KiGGS baseline study
Boys ≥13 years KiGGS Wave 2

SX1 neg. turn SX1 pos. SX1 neg. turn SX1 pos.
SX1 pos. turn SX1 neg. SX1 pos. turn SX1 neg.
ABSTRACT
Allergic sensitisations during the life course

Results
Data from the KiGGS baseline study show that 30% of girls aged 3 years or older and 39% of boys from the same age group (which is significantly more) were found to be sensitive to at least one of eight major inhalant allergens; in other words, their SX1 test proved positive. Most of these children also continued to have positive SX1 sensitisation a good ten years later (Figure 1). Only a small proportion of girls (11%) and boys (6%) who had shown sensitisation during the baseline study no longer did so during Wave 2. Among the girls and boys who showed no SX1 sensitisation at the time of the KiGGS baseline study, the probability of becoming sensitised was 21% and 29% respectively (a statistically significant difference). This also means that 79% of girls and 71% of boys remained SX1-negative after a good ten years.

Discussion
This study identified clear positive transition probabilities for sensitisation to a mix of eight major inhalant allergens (SX1 test) for the 10-year follow-up among both genders. As such, a far greater level of SX1 sensitisation developed over the life course than receded. Overall, this development, which was more pronounced among boys than girls, reflects the typical differences in gender and age in the incidence of IgE-mediated allergic diseases. The results underscore the need to further study the factors linked to immune system dysregulation, especially among children with a genetic predisposition to allergies. This would enable relevant preventive and therapeutic measures to be developed.

Data protection and ethics
KiGGS Wave 2 is subject to strict compliance with the data protection provisions set out in the Federal Data Protection Act. Hannover Medical School’s ethics committee assessed the ethics of the study and provided its approval (No. 2275-2014). Participation in the study was voluntary. The participants and/or their parents/legal guardians were also informed about the aims and contents of the study, and about data protection. Informed consent was obtained in writing.

Funding
KiGGS is funded by the Federal Ministry of Health and the Robert Koch Institute.

Conflicts of interest
The authors declared no conflicts of interest.

Corresponding author
Dr Roma Thamm
Robert Koch Institute
Department of Epidemiology and Health Monitoring
General-Pape-Str. 62–66
D-12101 Berlin, Germany
E-mail: ThammR@rki.de

Please cite this publication as
Allergic sensitisations during the life course

Acknowledgement
Foremost we would like to express our gratitude to both the participants and their parents. We would also like to thank everyone at the 167 study sites who provided us with space and active support on site.

KiGGS Wave 2 could not have been conducted without the dedication of numerous colleagues at the Robert Koch Institute. We would especially like to thank the study teams for their excellent work and their exceptional commitment during the three-year data collection phase.

References
   http://www.rki.de/journalhealthmonitoring-en (As at 15.03.2018)
   http://edoc.rki.de/oa/articles/revpaHQ3DqMU/PDF/25Pxm2f-cHqRM.pdf (As at 27.09.2017)
Allergic sensitisations during the life course

Imprint

Journal of Health Monitoring

Publisher
Robert Koch Institute
Nordufer 20
D-13353 Berlin, Germany

Editors
Susanne Bartig, Johanna Gutsche, Dr Birte Hintzpeter, Dr Franziska Prütz, Martina Rabenberg, Alexander Rommel, Stefanie Seeling, Martin Thißen, Dr Thomas Ziese
Robert Koch Institute
Department of Epidemiology and Health Monitoring
Unit: Health Reporting
General-Pape-Str. 62–66
D-12101 Berlin
Phone: +49 (0)30-18 754-3400
E-mail: healthmonitoring@rki.de
www.rki.de/journalhealthmonitoring-en

Typesetting
Gisela Dugnus, Alexander Krönke, Kerstin Möllerke

Translation
Simon Phillips/Tim Jack

ISSN 2511-2708

Note
External contributions do not necessarily reflect the opinions of the Robert Koch Institute.